Shares of consumer health company Kenvue ($KVUE) have plunged following the Trump administration’s announcement that Tylenol use during pregnancy ...

Moderately bullish activity in Kenvue Inc (KVUE), with shares down 10c near $16.12. Options volume roughly in line with average with 126k ...

While Kenvue's Tylenol has attracted intense political pressure, speculators are determined to make KVUE stock great again.

Aaron Siri is leading legal efforts on policies that dovetail with parts of Health Secretary Robert F. Kennedy Jr.’s ...

Cracker Barrel's latest efforts to show investors that it's working to turn things around include some management changes and ...

The maker of Tylenol is pushing back against resurfaced claims that its popular pain reliever is unsafe for pregnant women.

Kenvue Inc. (NYSE:KVUE) is one of the best most oversold large cap stocks so far in 2025. On October 1, Barclays lowered the ...

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare ...

Promotion of unproven claims from President Trump and RFK Jr. linking acetaminophen (Tylenol) to autism have significantly ...

The review is intended to “reduce complexity, improve execution and accelerate growth,” says a company spokesperson.

Cullen Capital Management, LLC disclosed the sale of 6,565,339 shares of Kenvue ( KVUE -0.67%) for the period ended Q2 2025.

Three medical experts with decades of experience in autism and epidemiology on Tuesday slammed Trump administration federal officials for spreading disinformation and distrust with new guidance ...